Stargardt Macular Degeneration
3 clinical trials · Condition
◉ Watch Stargardt Macular Degeneration
| Record | Firm | Date |
|---|---|---|
| A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) (NCT06942572) | Splice Bio | 2025-02-11 |
| Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) (NCT04239625) | Alkeus Pharmaceuticals, Inc. | 2019-12-20 |
| Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease (NCT02402660) | Alkeus Pharmaceuticals, Inc. | 2015-08-01 |
Track Stargardt Macular Degeneration automatically
Every clearance here is in the API, with alerts when new ones post.